Results 131 to 140 of about 1,758,994 (174)

The NeuroImmunoEndocrine Circuit of Umami Peptides: A Systems Biology Approach. [PDF]

Nutrients
Hemmati S, Mohagheghzadeh A.
europepmc   +1 more source

Design, Synthesis and Biological Evaluation of Medicinal Potential Compounds. [PDF]

Molecules
Boto REF, Almeida P, Silvestre SM.
europepmc   +1 more source

Development of Novel Gastrin-Releasing Peptide Receptor-Targeted Radioligand with Albumin Binder to Improve Accumulation in Tumor. [PDF]

ACS Med Chem Lett
Tsuchihashi S, Nakashima K, Watanabe H, Ono M.   +3 more
europepmc   +1 more source

Emerging roles of lipocalin-2-mediated neuroimmune interactions in chronic pain and itch. [PDF]

Front Pharmacol
Sun S, Lin J, Wang X, Liu T, Zhou G, Kang P.   +5 more
europepmc   +1 more source

Phase I Clinical Study with the GRPR-Antagonist [^99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference? [PDF]

Pharmaceutics
Orlova A, Rybina A, Medvedeva A, Zelchan R, Bragina O, Tashireva L, Larkina M, Varvashenya R, Lushnikova N, Kanellopoulos P, Maina T, Nock BA, Tolmachev V, Chernov V.   +13 more
europepmc   +1 more source

Mechanisms of pruritus and advances in traditional Chinese medicine therapy (Review). [PDF]

Mol Med Rep
Zhang H, Li Y, Liu Y, Feng D, Zhao L, Chen R, Zhang X, Dou J.   +7 more
europepmc   +1 more source

Bombesin/oligoarginine fusion peptides for gastrin releasing peptide receptor (GRPR) targeted gene delivery

Bioorganic and Medicinal Chemistry, 2018
The development of non-viral gene delivery systems, with the capacity to overcome most of the biological barriers facing gene delivery, is challenging. We have developed peptide-based, multicomponent, non-viral delivery systems, incorporating: a bombesin peptide ligand (BBN(6-14)), to selectively target the gastrin releasing peptide receptor (GRPR ...
Istvan Toth, Anjuman Ara Begum, Yu Wan
exaly   +7 more sources

Linker modifications in radiolabeled RM26-based antagonists to gastrin-releasing peptide receptor (GRPR) improved tracers’ pharmacokinetics

European Journal of Pharmaceutical Sciences
Radionuclide targeting of gastrin-releasing peptide receptor (GRPR) holds significant diagnostic and therapeutic potential, particularly in PSMA-negative/low-grade prostate cancer, estrogen receptor-positive breast cancer, and other malignancies. Recently, our group reported the development and results of the Phase I clinical evaluation of [99mTc]Tc ...
Anna Orlova, Ekaterina Bezverkhniaia, Panagiotis Kanellopoulos   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Gastrin-releasing peptide receptor (GRPR) locus in Japanese subjects with autism

Brain and Development, 2004
Gastrin-releasing peptide receptor (GRPR) gene is considered a candidate locus for infantile autism for several reasons. The present study investigated two polymorphic sites (C/450/T and C/661/T) in the second exon of the GRPR gene in Japanese patients with autism (DSM-IV) and healthy subjects.
Tadashi Umekage, Chieko Kato
exaly   +3 more sources

Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP)

Biochemical Pharmacology, 2005
The bombesin (Bn) receptor family includes the gastrin-releasing peptide (GRPR) and neuromedin B (NMBR) receptors, Bn receptor subtype 3 (BRS-3) and Bn receptor subtype 4 (BB(4)). They share 50% homology, yet their affinities for gastrin-releasing peptide (GRP) differ. The determinants of GRP high affinity for GRPR and BB(4), and low affinity for BRS-3
Michael Schumann, Robert Jensen, Jose A Tapia   +2 more
exaly   +3 more sources